via National Cancer Institute
Alfred/Monash led global trial reveals life saving drug for people with acute myeloid leukaemia (AML)
A landmark paper published 24 December in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30% improvement in survival in patients with acute myeloid leukaemia (AML).
The Phase 3 clinical trial called QUAZAR, showed that a drug, called CC-486, significantly improved survival in older patients, over the age of 55, with the disease. AML is the most acute blood cancer in adults and its incidence increased with age, with a poor prognosis. With current treatments, the majority of older patients will die of their disease within 2 years of diagnosis.
Each year in Australia almost 1000 people are diagnosed with AML.
The global trial, led by Professor Andrew Wei from the Monash University Australian Centre for Blood Diseases and a haematologist at Alfred Health, focused on people with AML over 55 years of age, “because of an unmet need to identify new agents able to improve outcome in patients after completing chemotherapy,” he said.
“After intensive chemotherapy, the risk of AML relapse is high. Many older patients are not eligible to receive a stem cell transplant and so a less toxic option to reduce disease recurrence is desirable, rather than just being monitored and waiting for the disease to come back. Based on the results of the QUAZAR study, it is very exciting to think that, by taking a tablet that is relatively well-tolerated, we can help reduce relapse risk and improve survival.”
The trial involved 472 patients, with an average age 68 years, who were either given CC-486 or a placebo.
Those receiving the drug – which has the added advantage of being a tablet that can be taken at home – had an average survival from remission of almost 25 months compared to those who did not take the drug, whose average survival was almost 15 months.
Following Professor Wei’s presentation of the results at the American Society for Hematology meeting in the United States last December, the Food and Drug Administration fast-tracked approval for the use of CC-486 in the U.S in September this year.
The data presented today in the NEJM is likely, according to Professor Wei, likely to establish a new standard of care for older patients with AML, “because our findings show that CC-486 significantly delays recurrence of the disease, thereby prolonging survival and without impacting on quality of life ” he said.
“This is a very significant advance because the drug is easy to administer and means that adults with AML don’t have to spend extra time in hospital.”
Professor Wei added that currently the drug is not approved for use in Australia.
See more:
- Wei at al. Oral Azacitidine Maintenance for Acute Myeloid Leukemia in First Remission. NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2004444
- Professor Andrew Wei’s ACBD research group
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Acute myeloid leukaemia
- Syria First Lady Diagnosed With Leukaemia: Presidency
Assad's wife Asma, who recovered from breast cancer in 2019, has been diagnosed with leukaemia, the president's office said on Tuesday.
- Syrian President's Wife Diagnosed with Acute Leukemia
Asma Assad, the wife of Syrian President Bashar Assad, has been diagnosed with acute myeloid leukemia (AML), according to a statement from his office on Tuesday.
- Syrian first lady diagnosed with leukemia
Asma Assad is suffering from the acute myeloid strain of the disease the presidency has revealed Asma Assad the wife of Syrian President ...
- Syrian First lady Asma Assad diagnosed with leukaemia: President's office
Syria's First Lady Asma Assad has been diagnosed with leukaemia, state news agency SANA reported, citing the President's office, on Tuesday. The Syrian Arab News Agency reported that the diagnosis of ...
- Syrian First Lady Diagnosed With Leukaemia
Wife of President Bashar al-Assad of Syria, Asma al-Assad, has been diagnosed with acute myeloid leukaemia, an official statement released by the President’s Office in Damascus disclosed, on Tuesday.
Go deeper with Google Headlines on:
Acute myeloid leukaemia
[google_news title=”” keyword=”acute myeloid leukaemia” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
QUAZAR
- Johnnie Robert Russell OBITUARY
Johnnie flourished in the arts, founding his own recording and promotion company Sonic Seasonings, and performing under the name Kid Quazar. In addition to his music he encapsulated his thoughts ...
- Albany man accused of attempting to rob tow company
Quazar Johnson, 23, faces multiple charges. According to the Albany County Sheriff’s Office, Johnson displayed a pocketknife at an employee while trying to retrieve a key fob that belonged to a ...
- Quazar Aberystwyth
Please note: The event information above has been added by the organiser. Whilst we try to ensure all details are up-to-date we do not make any warranty or representation as to the accuracy or ...
- Decarbonising construction with Graphene
GIM was founded by Manchester University graduate, Dr. Vivek Koncherry, who recently signed an MoU with Quazar Investment Company to create a new company in the UAE. This will be one of the most ...
- Manchester spin-out signs $1 billion game-changing deal to help tackle global sustainability challenges
UK-based Graphene Innovations Manchester Ltd (GIM), founded by University graduate Dr Vivek Koncherry, has signed a Memorandum of Understanding (MoU) with Quazar Investment Company to create a new ...
Go deeper with Google Headlines on:
QUAZAR
[google_news title=”” keyword=”QUAZAR” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]